Absorbable drugs biotech Innocoll sets terms for $75 million IPO

By
A A A

Innocoll, which develops collagen-based products to treat pain, foot infections and adhesions, announced terms for its IPO on Tuesday. The Athlone, Ireland-based company plans to raise $75 million by offering 5.4 million ADSs at a price range of $13 to $15. At the midpoint of the proposed range, Innocoll would command a fully diluted market value of $292 million.

Innocoll, which was founded in 1997 and booked $5 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol INNL. Piper Jaffray and Stifel are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: INNL

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Can You Talk Sexy Money?
Can You Talk Sexy Money?            

Stocks

Referenced

100%

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com